NCT01898065

Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer

Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Institut Cancerologie de l'Ouest · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

With functional imaging development, it becomes possible to increase radiation dose to radioresistant areas (located inside tumor volume) using radiotherapy dose-painting. This strategy is particularly suitable for prostate cancer where tumor hypoxia plays a major role in the resistance of these tumors to radiation. In order to develop intratumoral hypoxia targeting by radiotherapy dose-painting areas, we should characterize changes in hypoxia before treatment and during radiotherapy. * If hypoxia does not change during radiotherapy, radiotherapy dose-painting strategy by an "integrated" boost is performed. * If hypoxia varied (increasing or incomplete regression), a "final" boost strategy of radiotherapy dose-painting(IMRT, stereotactic brachytherapy or high dose rate) after a first fractionated IMRT could be considered. This study should show that PET imaging with fluoromisonidazole (18F-MISO) is an available tool to physicians in assessing tumor hypoxia.

Conditions

• Prostate Adenocarcinoma

Interventions

Type	Name	Description
DRUG	18-F-MISO	PET scan with the 18 Fluoro Misonidazole

Timeline

• Start date: 2012-06-01
• Primary completion: 2014-11-01
• Completion: 2015-02-01
• First posted: 2013-07-12
• Last updated: 2015-11-09

Locations

2 sites across 1 country: France